Skip to main content

Hagen Brett R's Form 4 filing

Kalaris Therapeutics, Inc. (KLRS) · filed Oct 24, 2022

Accession no.
0000899243-22-034057
Filed
Oct 24, 2022
Trade date
Oct 19-24, 2022
Filing delay
5 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $115.3K. It was filed 5 days after the trade, past the 2-business-day deadline.

This filing was later replaced by the amendment 0000899243-22-034263 (Oct 26, 2022). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hagen Brett RCIK 0001681782Officer (Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 19, 2022Common StockSSaleDisposed−345$9.36F2−$3,229.2113,233Direct
Oct 21, 2022Common StockSSaleDisposed−11,334$8.45F3−$95,772.3101,899Direct
Oct 24, 2022Common StockSSaleDisposed−2,000$8.13F5−$16,26099,899Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.27 to $8.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)